Literature DB >> 12223082

Mechanisms of tumour invasion and metastasis: emerging targets for therapy.

John T Price1, Erik W Thompson.   

Abstract

The progression of a tumour from one of benign and delimited growth to one that is invasive and metastatic is the major cause of poor clinical outcome in cancer patients. The invasion and metastasis of tumours is a highly complex and multistep process that requires a tumour cell to modulate its ability to adhere, degrade the surrounding extracellular matrix, migrate, proliferate at a secondary site and stimulate angiogenesis. Knowledge of the process has greatly increased and this has resulted in the identification of a number of molecules that are fundamental to the process. The involvement of these molecules has been shown to relate not only to the survival and proliferation of the tumour cell but, also to the processes of tumour cell adhesion, migration, and the tumour cells ability to degrade and escape the primary site as well as play a role in angiogenesis. These molecules may provide important therapeutic targets that represent the ability to target specific steps in the process of invasion and metastasis and provide additional therapies. The review focuses on representative key targets in each of these processes and summarises the state of play in each case.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12223082     DOI: 10.1517/14728222.6.2.217

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  34 in total

1.  Gossypol inhibits growth, invasiveness, and angiogenesis in human prostate cancer cells by modulating NF-κB/AP-1 dependent- and independent-signaling.

Authors:  Jiahua Jiang; Veronika Slivova; Andrej Jedinak; Daniel Sliva
Journal:  Clin Exp Metastasis       Date:  2011-12-14       Impact factor: 5.150

2.  CXCR4 regulates the early extravasation of metastatic tumor cells in vivo.

Authors:  Peter Gassmann; Jörg Haier; Kerstin Schlüter; Britta Domikowsky; Claudia Wendel; Ulrike Wiesner; Robert Kubitza; Rainer Engers; Stephan W Schneider; Bernhard Homey; Anja Müller
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

3.  Ganoderma lucidum (Reishi) inhibits cancer cell growth and expression of key molecules in inflammatory breast cancer.

Authors:  Michelle M Martínez-Montemayor; Raysa Rosario Acevedo; Elisa Otero-Franqui; Luis A Cubano; Suranganie F Dharmawardhane
Journal:  Nutr Cancer       Date:  2011-09-02       Impact factor: 2.900

4.  The prognostic significance of serum and cerebrospinal fluid MMP-9, CCL2 and sVCAM-1 in leukemia CNS metastasis.

Authors:  Meng-Ya Si; Zhi-Cheng Fan; Ya-Zhen Li; Xiao-Lan Chang; Qing-Dong Xie; Xiao-Yang Jiao
Journal:  J Neurooncol       Date:  2015-01-30       Impact factor: 4.130

5.  Liver X receptor α (LXRα) promoted invasion and EMT of gastric cancer cells by regulation of NF-κB activity.

Authors:  Linhua Ji; Bin Zhang; Gang Zhao
Journal:  Hum Cell       Date:  2017-01-16       Impact factor: 4.174

6.  Immunohistochemical characterization of brain-invasive meningiomas.

Authors:  Thomas Backer-Grøndahl; Bjørnar H Moen; Magnus B Arnli; Kathrin Torseth; Sverre H Torp
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

7.  Antimetastatic effects of licochalcone A on oral cancer via regulating metastasis-associated proteases.

Authors:  Huan Shen; Guang Zeng; Guo Tang; Xingwei Cai; Lixia Bi; Changcheng Huang; Yongjin Yang
Journal:  Tumour Biol       Date:  2014-05-01

Review 8.  Profiling distinct mechanisms of tumour invasion for drug discovery: imaging adhesion, signalling and matrix turnover.

Authors:  Neil O Carragher
Journal:  Clin Exp Metastasis       Date:  2008-10-29       Impact factor: 5.150

Review 9.  Heme oxygenase-1 in tumors: is it a false friend?

Authors:  Alicja Jozkowicz; Halina Was; Jozef Dulak
Journal:  Antioxid Redox Signal       Date:  2007-12       Impact factor: 8.401

Review 10.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.

Authors:  Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.